E-viri
Recenzirano
Odprti dostop
-
van Dyck, Christopher H.; Swanson, Chad J.; Aisen, Paul; Bateman, Randall J.; Chen, Christopher; Gee, Michelle; Kanekiyo, Michio; Li, David; Reyderman, Larisa; Cohen, Sharon; Froelich, Lutz; Katayama, Sadao; Sabbagh, Marwan; Vellas, Bruno; Watson, David; Dhadda, Shobha; Irizarry, Michael; Kramer, Lynn D.; Iwatsubo, Takeshi
The New England journal of medicine, 01/2023, Letnik: 388, Številka: 1Journal Article
In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognition and function at 18 months than those who received placebo.
